Fundraising Fox
/Companies
Sign in

Asgard Therapeutics

Lund, SE · Founded 2018 · 29 employees on LinkedIn · 5 known investors

Find your way into Asgard Therapeutics

Sign up to see every warm intro you have to Asgard Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Asgard Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses. The company focuses on oncology immunotherapy through its TrojanDC approach.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

Asgard Therapeutics was founded in 2018 by Cristiana Pires, Fábio Rosa, and Filipe Pereira.

CPCristiana Pires
Cristiana PiresCo-founder and CEO
FRFábio Rosa
Fábio RosaCo-founder and VP of ResearchFábio Rosa studied transcription factors and cellular reprogramming during his research career, focusing on methods to induce dendritic cell fate. He is co-founder and VP of Research at Asgard Therapeutics, a cancer immunotherapy company developing direct cell reprogramming technologies.
FPFilipe Pereira
Filipe PereiraCo-founder and Head of InnovationFilipe Pereira is a Professor of Molecular Medicine at Lund University with 20 years of research experience in cellular reprogramming and immunology. He earned his Ph.D. from Imperial College London and conducted postdoctoral research at Mount Sinai, where he developed approaches to apply cellular reprogramming to hematopoiesis; he co-founded Asgard Therapeutics to translate dendritic cell reprogramming into cancer immunotherapy.

Investors · 5

LU Innovationlisted by LU InnovationLund

How we know: LU Innovation's portfolio page · Not right? Tell us

Novo Holdingslisted by Novo HoldingsHellerup · $1.1M – $54M

How we know: Novo Holdings's portfolio page · funding news · asgardthx.com · Not right? Tell us

RV Invest GmbHlisted by RV Invest GmbHRavensburg

How we know: RV Invest GmbH's portfolio page · Not right? Tell us

Boehringer Ingelheim Venture FundreportedIngelheim am Rhein · $16.2M

How we know: funding news · asgardthx.com · open dataset · 5k.vc investor directory · Not right? Tell us

Funding

SEC filings, press & company announcements

$30M disclosed across 1 of 2 rounds · 2021–2024

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncologyprnewswire.com · Mar 2024Asgard Therapeutics Raises €30M in Series A Financingfinsmes.com · Mar 2024Team – ASGARD THERAPEUTICSasgardthx.com · Mar 2022Asgard Therapeutics raises EUR 6M in Seed Financing to exploit direct in vivo reprogramming - Asgard Therapeuticsasgardthx.com · Nov 2021

Frequently asked questions

What does Asgard Therapeutics do?
Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses. The company focuses on oncology immunotherapy through its TrojanDC approach.
Who founded Asgard Therapeutics?
Asgard Therapeutics was founded by Cristiana Pires, Fábio Rosa, Filipe Pereira in 2018.
Who are Asgard Therapeutics's investors?
Asgard Therapeutics's investors include Industrifonden, LU Innovation, Novo Holdings, RV Invest GmbH, Boehringer Ingelheim Venture Fund.
How much funding has Asgard Therapeutics raised?
Asgard Therapeutics has disclosed $30M raised across 1 of its 2 known rounds.
Where is Asgard Therapeutics headquartered?
Asgard Therapeutics is headquartered in Lund, SE.